*** Please send Forms to the appropriate Fax Numbers ***
| Drug Class | HCPS Codes | Brand / Generic Names | PA Form Link |
|---|---|---|---|
| Actemra | J3262, Q5133 |
Actemra (tocilizumab), Tofidence (tocilizumab-bavi) |
Prior Authorization |
| Adakveo | J0791 |
Adakveo (crizanlizumab-tmca) |
Prior Authorization |
| Adstiladrin | J9029 |
Adstiladrin (nadofaragene firadenovec-vncg) |
Prior Authorization |
| ALS Agents | J1301, J1304 |
Radicava (edaravone), Qalsody (tofersen) |
Prior Authorization |
| Alzheimer's Drugs | J0172, J0174 |
Aduhelm (aducanumab-avwa), Leqembi (lecanemab-irmb) |
Prior Authorization |
| Amyloidosis | J0222 |
Onpattro (patisiran) |
Prior Authorization |
| Analgesics | J7336, J2278 |
Qutenza (capsaicin 8% patch), Prialt (ziconotide) |
Prior Authorization |
| Androgens | S0189 |
TESTOPEL (testosterone pellets) |
Prior Authorization |
| Anemia | J0896, J1302 |
Reblozyl (luspatercept-aamt), Enjaymo (sutimlimab-jome) |
Prior Authorization |
| Anti-Hemophilic: Factor I | J7177, J7178 | Human Fibrinogen Concentrate & NOS | Prior Authorization |
| Anti-Hemophilic: Factor III | J7196, J7197 |
Antithrombin III (Recombinant), Antithrombin III (Human) 1IU |
Prior Authorization |
| Anti-Hemophilic: Factor IX | J7193, J7194, J7195, J7200, J7201, J7202, J7203 |
FACTOR IX (Non-Recombinant, Complex, Recombinant NOS), Alprolix, Idelvion, Rebinyn, Rixubis |
Prior Authorization |
| Anti-Hemophilic: Factor VII | J7189, J7212 |
FACTOR VII (Recombinant) 1IU NOVOSeven, SEVENFact
|
Prior Authorization |
| Anti-Hemophilic: Factor VIII | J7182, J7185, J7188, J7190, J7191, J7192, J7204, J7205, J2707, J7208, J7209, J7210, J7211 | FACTOR VIII (Human, Pegylated-Recombinant), Fusion-Recombinant, Recombinant NOS, (Porcine), Afstyla, Jivi, Kovaltry, Novoeight, Nuwiq, Obizur, Xyntha, Esperoct, Eloctate, Adynovate, | Prior Authorization |
| Anti-Hemophilic: Factor VIII + VWF | J7183, J7186, J7187 |
FACTOR VIII PLUS VWF Complex (Human) 1IU, Humate, Wilate |
Prior Authorization |
| Anti-Hemophilic: Factor X | J7175 | Factor X (Human) 1IU. Coagadex | Prior Authorization |
| Anti-Hemophilic: Factor XIII | J7180, J7181 |
FACTOR XIII (Human), FACTOR XIII (Recombinant) |
Prior Authorization |
| Anti-Neoplastics: B-Cell Lymphoma | J0202, J9039, J9229, J9286, J9309, J9321, J9359, Q2041 |
Besponsa (inotuzumab ozogam), Blincyto (blinatumomab), Campath/Lemtrada (alemtuzumab), Columvi (glofitamab-gxbm), Epkinly (epocoritamab-bysp), Polivy (polatuzumab), Zynlonta (loncastuximab tesirine-lpyl), Yescarta (axicabtagene ciloleucel) |
Prior Authorization |
| Anti-Neoplastics: Breast Cancer | J9207, J9258, J9264, J9306, J9316, J9395 | Abraxane (paclitaxel, protein bound), Faslodex (fulvestrant), Ixempra (ixabepilone), Perjeta (pertuzumab), Phesgo (pertuzumab/ trastuzumab/ hyaluronidase-zzxf), Teva-Brand (paclitaxel, protein-bound) | Prior Authorization |
| Anti-Neoplastics: Colorectal | J9400, J9055, J9303 |
Zaltrap (ziv-aflibercept), Erbitux (cetuximab), Vectibix (panitumumab) |
Prior Authorization |
| Anti-Neoplastics: Liposarcoma | J9179, J9352 |
Halaven (eribulin mesylate), Yondelis (trabectedin) |
Prior Authorization |
| Anti-Neoplastics: Lymphoid | J9019, J9020, J9021, J9033, J9034, J9036, J9118, J9262, J9266, J9301, J9302 |
Arzerra/Kesimpta (ofatumumab), Bendeka/Treanda/Belrapzo (bendamustine HCl), Erwinaze (asparaginase erwinia chrysanthemi), Gazyva (obinutuzumab), Oncaspar (pegaspargase), Rylaze (asparaginase), Asparlas (calaspargase pegol-mknl), Synribo (omacetaxine mepesuccinate) |
Prior Authorization |
| Anti-Neoplastics: Lymphoid, Follicular | J9057 |
Aliqopa (copanlisib) |
Prior Authorization |
| Anti-Neoplastics: Melanoma | J9015, J9274, J9298, J9325 |
Proleukin (aldesleukin), Kimmtrak (tebentafusp-tebn), Opdualag (nivolumab/relatilmab-rmbw), Imlygic (talimogene laherparepvec) |
Prior Authorization |
| Anti-Neoplastics: Multiple Myeloma | J1323, J3055, J9047, J9144, J9145, J9148, J9176, J9227, J3399, Q2055, Q2056 |
Zolgensma (onasemnogene), Darzalex (daratumumab), Darzalex Faspro (daratumumab/ hyaluronidase-fihj), Empliciti (elotuzumab), Kyprolis (carfilzomib), Sarclisa (isatuximab-irfc), Elrexfio (elranatamab-bcmm), Talvey (talquetamab-tgvs), Tecvayli (teclistamab-cqyv), Abecma (idecabtagene vicieucel), Carvykti (ciltacabtagene autoleucel) |
Prior Authorization |
| Anti-Neoplastics: Prostate Cancer | J9043, J9155, Q2043 | Degarelix (degarelix acetate), Jevtana (Cabazitaxel), Provenge (sipuleucel-T) | Prior Authorization |
| Anti-Neoplastics: Renal | J9023, J9330 | Bavencio (avelumab), Torisel (temsirolimus) | Prior Authorization |
| Anti-Neoplastics: T-Cell / Hairy Lymphoma | J9042, J9160, J9268, J9307, J9315, J9318, J9319 | Adcetris (brentuximab vedotin), Romidepsin (generic), Folotyn (pralatrexate inj), Istodax (romidepsin), Nipent (pentostatin), Lymphir (denileukin diftitox) | Prior Authorization |
| Anti-Neoplastics: Opdivo | J9299 | Opdivo (nivolumab) | Prior Authorization |
| Anti-Neoplastics: Tecentriq | J9022 | Tecentriq (atezolizumab) | Prior Authorization |
| Anti-Neoplastics: Valstar | J9357 | Valstar (valrubicin) | Prior Authorization |
| Anti-Neoplastics: Yervoy | J9228 | Yervoy (ipilimumab) | Prior Authorization |
| Anti-Rheumatic | J0129 |
Orencia (abatacept) |
Prior Authorization |
| Arcalyst | 2793 |
Arcalyst (rilonacept) |
Prior Authorization |
| Asthma: Non-Specific | J2356 |
Tezspire (tezepelumab-ekko) |
Prior Authorization |
| Brineura | J0567 |
Brineura (cerliponase alfa) |
Prior Authorization |
| Castleman's Disease | J2860 | Sylvant (siltuximab) | Prior Authorization |
| CHAPLE Disease | J9376 |
Veopoz (pozelimab-bbfg) |
Prior Authorization |
| Chemotherapy NOC | J9999 |
Chemotherapy Not Otherwise Classified Agents |
Prior Authorization |
| Coagulants / Hemophilia | J1411, J7170, J7198 |
Hemgenix (etranacogene dezaparvovec-drlb), Hemlibra (emicizumab-kxwh), AICC |
Prior Authorization |
| Coagulants / Hemophilia NOC | J7199 | Hemophilia/Clotting Factor Not Otherwise Classified | Prior Authorization |
| Colony Stimulating Factors (Leukine) | J2820 |
Leukine (sargramostim) |
Prior Authorization |
| Covid 19 Drugs | J0248, Q0222, Q0224 |
Veklury (remdesivir), bebtelovimab, Pemgarda (pemivibart) |
Prior Authorization |
| Danyelza | J9348 |
Danyelza (naxitamab-gqgk) |
Prior Authorization |
| Dopamine Agonists | J0364 | Apokyn / Kynmobi (apomorphine) | Prior Authorization |
| Drugs-Biologics NOC | C9399, J3490, J3590 |
Drugs / Biologics Not Otherwise Classified |
Prior Authorization |
| Duchenne Muscular Dystrophy | J1413, J1426, J1427, J1428, J1429 | Amondys (casimersen), Viltepso (viltolarsen), Exondys (eteplirsen), Vyondys (golodirsen) | Prior Authorization |
| Elahere | C9146 | Elahere (mirvetuximab soravtansine-gynx), Elevidys (delandistrogene moxeparvovec-rokl), | Prior Authorization |
| Elzonris | J9269 | Elzonris (tagraxofusp-erzs) | Prior Authorization |
| Enzymes and Enzymatics | J0180, J0221, J0257, J0775, J1322, J1458, J1786, J1931, J2783, J3060, J3385, | Aldurazyme (laronidase), Vimizim (elosulfase alfa), Cerezyme (imiglucerase), Elelyso (taliglucerase alfa), VPRIV (velaglucerase), Elitek (rasburicase), Fabrazyme (agalsidase), Glassia (alpha 1 proteinase inhibitor), Lumizyme / Myozyme (alglucosidase alfa), Naglazyme (galsulfase), Xiaflex (collagenase, clostridium histolyticum) | Prior Authorization |
| Fabry's Disease | J0180, J1413, J8499 | Elfabrio (pegunigalsidase alfa-iwxj), Fabrazyme (agalsidase beta), Galafold (migalastat) | Prior Authorization |
| Fyarro | J9331 | Fyarro (sirolimus protein-bound) | Prior Authorization |
| Gamifant | J9210 | Gamifant (emapalumab-lzsg) | Prior Authorization |
| Geographic Atrophy | J2781, J2782 | Syfovre (pegcetacoplan), Izervay (avacincaptad pegol) | Prior Authorization |
| GI Biologic | J3380 | Entyvio (vedolizumab) | Prior Authorization |
| Givosiran | J0223 | Givosiran injection | Prior Authorization |
| Gonadotropin | J1675, J9225, J9226 | Supprelin LA (implant), Vantas (implant) [histrelin acetate] | Prior Authorization |
| Gout | J2507 | Krystexxa (Pegloticase) | Prior Authorization |
| Graves Disease | J3241 | TEPEZZA (teprotumumab-trbw) | Prior Authorization |
| Growth Hormone Antagonist | J2170, J2502 | Increlex (mecasermin), Signifor LAR (pasireotide) | Prior Authorization |
| Hematological | J2562, J2796 | Mozobil (plerixafor), Nplate (romiplostim) | Prior Authorization |
| Ilaris | J0638 | Ilaris (canakinumab) | Prior Authorization |
| Immune Globulins | J7504, J7511 | Atgam (antithymocyte globulin equine), Thymoglobulin (antithymocyte globulin rabbit) | Prior Authorization |
| Immune Modulators | J2323 | Tysabri (natalizumab) | Prior Authorization |
| Immunosuppressives NOC | J7599 | Immunosuppressive Drugs Not Otherwise Classified | Prior Authorization |
| IVIG: Hep B | J1571, J1573 | Hepagam B [IM], Hepatitis B immune globulin [IV] | Prior Authorization |
| Jemperli | J9272 | Jemperli (dostarlimab-gxly) | Prior Authorization |
| Jelmyto | J9281 | Jelmyto (mitomycin pyelocalyceal instillation) | Prior Authorization |
| Jetrea | J7316 | Jetrea (ocriplasmin) | Prior Authorization |
| Kanuma | J2840 | Kanuma (sebelipase alfa) | Prior Authorization |
| Knee Cartilage Drugs | J7330 | Carticel (Autologous cultured chondrocytes, implant) | Prior Authorization |
| Lamzede | J0217 | Lamzede (velmanase alfa-tycv) | Prior Authorization |
| Lartuvo | J9285 | Lartuvo (olaratumab) | Prior Authorization |
| Libtayo | J9119 | Libtayo (cemiplimab-rwlc) | Prior Authorization |
| Lutetium | A9513, A9607 | Lutathera (lutetium lu 177 dotatate), Pluvicto lutetium lu 177 vipivotide tetraxetan) | Prior Authorization |
| Mepsevii | J3397 | Mepsevii (vestronidase alfa-vjbk) | Prior Authorization |
| Metabolic Drugs | J1743 | Eleprase (idursulfase) | Prior Authorization |
| Mineral Deficiency | J0584, J0606, J0630 | Crysvita (burosumab-twza), Parsabiv (etelcalcetide), Miacalcin (calcitonin salmon) | Prior Authorization |
| Mitosol | J7315 | Mitosol (mitomycin, ophthalmic) | Prior Authorization |
| Myasthenia Gravis | J9332, J9333 | Vyvgart (efgartigimod alfa-fcab), Rystiggo (rozanolixizumab-noli) | Prior Authorization |
| Neuro-Muscular Blockers | J0585, J0586, J0587, J0588, J0589 |
Botox (onabotulinumtoxin), Dysport (abobotulinumtoxin A), Myobloc (rimabotulinumtoxin B), Xeomin (incobotulinumtoxin A), Daxxify (daxibotulinumtoxina-lanm) |
Prior Authorization |
| NMOSD | J1823 | Uplizna (inebilizumab-cdon) | Prior Authorization |
| Ophthalmic Implants | J7311, J7312 | Retisert (fluocinolone acetonide), Ozurdex (dexamethasone) | Prior Authorization |
| Ophthalmic Other | J3396 | Visudyne (verteporfin inj) | Prior Authorization |
| Opioid Agonists | J0570, J0577, J0578, J0592, Q9991, Q9992 | Brixadi (buprenorphine ER), Probuphine (buprenorphine implant), Buprenex (buprenorphine), Sublocade (buprenorphine XR) | Prior Authorization |
| Oxlumo | J0224 | Oxlumo (lumasiran) | Prior Authorization |
| Padcev | J9177 | Padcev (enfortumab vedotin-ejfv) | Prior Authorization |
| Pancreatic Cancer | J9205 | Onivyde (irinotecan lipsome) | Prior Authorization |
| Pompe Disease | J0219, J0220, J1202, J1203 | Nexviazyme (avalglucosidase alfa-ngpt), Lumizyme (alglucosidase alfa), Opfolda (miglustat), Pombiliti (cipaglucosidase alfa-atga) | Prior Authorization |
| Poteligeo | J9204 | Poteligeo (mogamulizumab-kpkc) | Prior Authorization |
| Roctavian | J1412 | Roctavian (valoctocogene roxaparvovec-rvox) | Prior Authorization |
| Ryplazim | J2998 | Ryplazim (plasminogen, human-tvmh) | Prior Authorization |
| Scenesse | J7352 | Scenesse (afamelanotide implant) | Prior Authorization |
| Somatropin Products | J2941 | Somatropin (Humatropin, etc) | Prior Authorization |
| Spinraza | J2326 | Spinraza (nusinersen) | Prior Authorization |
| Thyroid Eye Disease | J3241 | Tepezza (teprotumumab-trbw) | Prior Authorization |
| Tivdak | J9273 | Tivdak (tisotumab vedotin-tftv) | Prior Authorization |
| Transplant | J0480, J0485 | Simulect (basiliximab), Nulojix (belatacept) | Prior Authorization |
| Trodelvy | J9317 | Trodelvy (sacituzumab govitecan-hziy) | Prior Authorization |
| Unituxin | J1246 | Unituxin (dinutuximab) | Prior Authorization |
| Vonvendi | J7179 | Vonvendi (Von Willebrand Factor, Recombinant) | Prior Authorization |
| Vyepti | J3032 | Vyepti (eptinezumab-jjmr) | Prior Authorization |
| Vyjuvek | J3401 | Vyjuvek (beremagene geperpavec-svdt) | Prior Authorization |
| Xenpozyme | J0218 | Xenpozyme (olipudase alfa-rpcp) | Prior Authorization |
| Zepzelca | J9223 | Zepzelca (lurbinectedin) | Prior Authorization |
| ST: Alpha-1 Proteinase Inhibitors | J0256 |
Prolastin-C (Human) |
Step Therapy Authorization |
| ST: Angioedema | J0593, J0596, J0597, J0598, J0599, J1290, J1744 |
Takhzyro (lanadelumab-flyo), Berinert / Cinryze / Ruconest / Haegarda (C-1 esterase inhibitor, human), Kalbitor (ecallantide), (Firazyr (icatibant acetate) |
Step Therapy Authorization |
| ST: Anti-Emetic | J1454 |
Akynzeo (fosnetupitant-palonosetron) |
Step Therapy Authorization |
| ST: Anti-Inflammatory | J0717, J1747, J2327, J3245, J1602, J3357, J3358 |
Cimzia (certolizumab pegol), Spevigo (spesolimab-sbzo), Skyrizi (risankizumab-rzaa), Ilumya (tildrakizumab), Simponi (Golimumab), Stelara (Ustekinumab; SubQ and IV) |
Step Therapy Authorization |
| ST: Anti-Neoplastic: AML | J9203, J9025 |
Mylotarg (gemtuzumab ozogamicin), Vidaza (azacitidine) |
Step Therapy Authorization |
| ST: Anti-Neoplastic: Mantle Cell Lymphoma | J9046, J9048, J9049, J9041 |
Bortezomib Products: Dr. Reddy’s, Fresenia, Hospira, bortezomib (velcade) |
Step Therapy Authorization |
| ST: Anti-Neoplastic: NSCLC | J1448, J9061, J9305, J9308, J9173 |
(Cosela (Trilaciclib), Rybrevant (amivantamab-vmjw), Portrazza (necitumumab), Cyramza (ramucirumab), Imfinzi (durvalumab) are non-preferred. The preferred products are pemetrexed biosimilars (NON-Pemfexy) |
Step Therapy Authorization |
| ST: Anti-Neoplastics: Keytruda | J9271 | Keytruda (pembrolizumab) | Step Therapy Authorization |
| ST: Anti-Neoplastic: Pemetrexed | J9304, J9294, J9296, J9297, J9305, J9314, J9324 |
Pemfexy, Pemrydi, Hospira, Accord, Sandz, Alimta, Teva |
Step Therapy Authorization |
| ST: Asthma | J0517, J2182, J2357, J2786, |
Fasenra (benralizumab), Cinqair (reslizumab), Nucala (mepolizumab), Xolair (omalizumab) |
Step Therapy Authorization |
| ST: Bone Resorption Inhibitors | J0897, J3490, J3111, J2430, J3489 | Prolia/Xgeva (denosumab), Tymlos and Evenity (romosozumab-aqqg) are non-preferred. The preferred products are pamidronate and zoledronic acid (no PA required) | Step Therapy Authorization |
| ST: Clostridium difficile (C-diff) | J1440, J0565 | Rebyota (fecal microbiota, live-jslm), Zinplava (bezlotoxumab) - (No PA required for most preferred Part D alts) | Step Therapy Authorization |
| ST: Colony Stimulating Factors (Long) | J2505, J2506, Q5108, Q5111, Q5120, Q5122, Q5127, Q5130 |
Neulasta, Fulphila, Udenyca, Nyvepria, Stimufend are non-preferred. The preferred products are Neulasta (ex bio), Fylnetra, Ziextenzo |
Step Therapy Authorization |
| ST: Colony Stimulating Factors (Short) | J1442, J1447, J1449, Q5110, Q5125, Q5101 |
Neupogen (filgrastim), Granix (tbo-filgrastim), Rolvedon (eflapregrastim-xnst), Nyvestym (filgrastim-aafi), Releuko (filgrastim-ayow) are non preferred. The preferred product is Zarxio (filgrastim-sndz) |
Step Therapy Authorization |
| ST: Complement Inhibitor | J1300, J1303 | Soliris (eculizumab) is non-preferred. The preferred product is Ultomiris (ravulizumab-cwvz) (Requires Prior Authorization) | Step Therapy Authorization |
| ST: Dyslipidemia | J1306 | Leqvio (inclisiran) is non-preferred. Preferred products are Part D PCSK9 inhibitors (Praluent, Repatha, No PA required) | Step Therapy Authorization |
| ST: Erythropoiesis Stimulating Agents | J0881, J0882, J0885, J0886, J0887, J0888, Q4081, Q5105, Q5106 | Aranesp (darbepoetin alfa) Epogen (epoetin alfa), and Procrit (epoetin alfa) are non-preferred. The preferred product is Retacrit (epoetin alpha-epbx), Mircera (epoetin beta), Epogen (biosimilar-epoetin alfa) | Step Therapy Authorization |
| ST: HIV Therapies | J1961 | Sunlenca (lenacapavir) is non-preferred. The preferred products are Part D HIV products (no PA required) | Step Therapy Authorization |
| ST: Humira | J0135, C9399 | Humira (adalimumab), Yuflyma (adalimumab-aaty), Simlandi (adalimumab-ryvk) | Step Therapy Authorization |
| ST: Infliximab | J1745, Q5103, Q5104, Q5121 | Remicade (infliximab), Renflexis (infliximab-abda), Avsola (infliximab-axxq) are non-preferred. The preferred product is Inflectra (infliximab-dyyb) | Step Therapy Authorization |
| ST: Iron Salts | J1437, Q0138, Q0139, J1439, J1443, J1750, J1756, J2916 | Monoferiric (derisomaltose), Feraheme (ferumoxytol), Injectafer (ferric carboxymaltose), Triferic (ferric pyrophosphate) are Non-preferred products. The preferred products are: Infed (iron dextran), Venofer (iron sucrose), Ferrlecit (sodium ferric gluconate cmplx)(No PA required) | Step Therapy Authorization |
| ST: IVIG | J1459, J1460, J1551, J1554, J1555, J1556, J1557, J1558, J1559, J1560, J1561, J1562, J1566, J1568, J1569, J1572, J1575, J1599 |
Asceniv [non-lyophilized], Bivigam, Cuvitru, Flebogamma, Gammagard, Gammaplex, Hizentra, HyQvia, IVIG liquid, IVIG powder, Xembify, are non-preferred. The preferred products are Gamunex, Octagam and Privigen |
Step Therapy Authorization |
| ST: Lupus | J0491, J0490 |
Saphnelo (anifrolumab-fnia) is non-preferred. The preferred product is Benlysta (belimumab) |
Step Therapy Authorization |
| ST: Multiple Sclerosis | J1595, J2329, J2350, J7513, Q5134 |
Ocrevus (ocrelizumab), Copaxone (Glatiramer acetate), Zenapax (daclizumab), Briumvi (ublituximab), Tyruko (natalizumab-sztn) are Non-preferred. The preferred products are Part D alternatives including Aubagio and generic glatiramer (no PA required for most preferred Part D alts). |
Step Therapy Authorization |
| ST: Ophthalmic (VEGF) Inhibitors |
J0177, J0178, J0179, J2503, J2777, J2778, J2779, J9035, Q5107, Q5118, Q5124, Q5126, Q5128, Q5129 |
Eylea (Aflibercept 2mg), Eylea HD (Aflibercept 8mg), Lucentis (Ranibizumab), Macugen (Pegaptanib), Beovu (Brolucizumab-dbll), Susvimo (ranibizumab), Vabysmo (faricimab-svoa), Byooviz (ranibizumab-nuna) are non-preferred. The preferred products are Intraocular: Avastin (Bevacizumab), Mvasi (Bevacizumab-awwb), Zirabev (bevacizumab-bvzr), Alymsys (bevacizumab-maly), Alymsys (bevacizumab-maly) and Vegzelma (bevacizumab-adcd) (no PA required) |
Step Therapy Authorization |
| ST: Parkinson's Disease | J7340 | Duopa is the non-preferred product. preferred products are Part D carbidopa/levodopa alternatives. | Step Therapy Authorization |
| ST: Pulmonary Arterial Hypertension | J1325, J3285, J7686, Q4074 | Tyvaso / Remodulin (treprostinil), Ventavis (iloprost), Flolan / Veletri (epoprostenol sodium) | Step Therapy Authorization |
| ST: Rituximab | J9311, J9312, Q5115, Q5119, Q5123 | Rituxan (rituximab) IV and Rituxan Hycela (rituximab/hyaluronidase human) are non-preferred. The preferred products are, Ruxience (rituximab-pvvr) and Riabni (rituximab-arrx) and Truxima (rituximab-abbs) IV | Step Therapy Authorization |
| ST: Somatostatin Agents | J1930, J1932, J2353, J2354 | Somatuline Depot (lanreotide acetate), Cipla (lanreotide), Sandostatin LAR (octreotide depot) are non-preferred. The preferred product is Sandostatin (octreotide non-depot). | Step Therapy Authorization |
| ST: Trastuzumab | J9354, J9355, J9356, J9358, Q5112, Q5113, Q5114, Q5116, Q5117 |
Kadcyla (ado-trastuzumab emt), Herceptin (trastuzumab) IV and Herceptin Hylecta (trastuzumab/hyaluronidase-oysk), Enhertu (fam-trastuzumab deruxtecan-nxki) are non-preferred. The preferred products are: Ontruzant (trastuzumab-dttb), Herzuma (trastuzumab-pkrb), Trazimera (trastuzumab-qyyp), Kanjinti (trastuzumab-anns), Ogivri (trastuzumab-dkst) |
Step Therapy Authorization |
| ST: Viscosupplements | J7321, J7323, J7324, J7325, J7326, J7327 |
Orthovisc, Monovisc are non-preferred. The preferred products are Synvisc [One], Euflexxa, Hyalgan/Supartz & Gel-One (Hyaluronate Sodium). (No PA required) |
Step Therapy Authorization |
| Future Class | Codes | Brand/Generic | Prior Authorization |
Privacy Policy | Cookie Policy | Terms and Conditions | Site Map | Y0084_WB © 2024 ATRIO Health Plans
